Sunlenca (lenacapavir) is used for the treatment of HIV-1 infection in heavily treatment-experienced people with multi-drug resistant (MDR) HIV-1 infection. Uses · Side effects · Before taking · Directions

Lenacapavir, a moderate CYP3A inhibitor, may increase the exposure to, and therefore potential risk of adverse reactions from, drugs primarily metabolized by ...

Sunlenca (300 mg tablet and 463.5 mg/1.5 mL injection) is a first-in-class, long-acting HIV capsid inhibitor approved in the United States, the United Kingdom, ...

Lenacapavir is a first-in-class capsid inhibitor being investigated for use in HIV-1 treatment. Identification · Products · Categories · References

Lenacapavir is always used in combination with other HIV medicines. Brand Name. Sunlenca. Drug Class. Capsid Inhibitors. Drug Database, Clinicalinfo.hiv.gov. 2 ...

First–in–class capsid inhibitor that targets HIV–1 at multiple stages of the HIV–1 lifecycle1,3. The capsid core contains and protects viral RNA and enzymes ...

Sunlenca is given when the virus is resistant to other treatments. Sunlenca contains the active substance lenacapavir. Overview · Product information · Product details

SUNLENCA is a prescription medication that is used with other human immunodeficiency virus-1 (HIV-1) medicines to treat HIV-1 infection in adults. Learn more about how it works · Dosing · Support

6 мар. 2023 г. · Lenacapavir is an HIV capsid inhibitor. The HIV capsid is a cone-shaped structure that provides a container for viral proteins and enzymes.